I doubt the license revenue will be below 10% of sales. There may be some allowance for initial marketing and launch expenses which might indicate this early on but my guess (and that is all) is that the license revenue will be around 15%. And for a unique product with little or no competition I think this would be the minimum rather than the maximum.
OTC pharmacy medicines are big money spinners for pharmacies as the supermarkets are not allowed to sell them and prescription drugs are only marginally profitable.
- Forums
- ASX - By Stock
- Vivagel BV treatment and prevention
I doubt the license revenue will be below 10% of sales. There...
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add SPL (ASX) to my watchlist
|
|||||
Last
9.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $39.17M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 28056 | 9.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
9.9¢ | 1285 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 28056 | 0.095 |
2 | 110498 | 0.094 |
1 | 26688 | 0.092 |
1 | 49413 | 0.091 |
2 | 22750 | 0.090 |
Price($) | Vol. | No. |
---|---|---|
0.099 | 1285 | 1 |
0.100 | 127980 | 5 |
0.105 | 70443 | 4 |
0.110 | 16500 | 2 |
0.115 | 109827 | 3 |
Last trade - 07.00am 27/08/2024 (20 minute delay) ? |
Featured News
SPL (ASX) Chart |
Day chart unavailable